The Shalem Lab develops novel screening paradigms to study neurodegenerative diseases and PQC pathways. This includes developing fluorescence sensors for protein aggregation, processing and stability followed by genome-wide CRISPR screening in human cell lines and neuronal and neuron-like cells derived from ESC and iPS cells.
In addition, the lab is developing its own analytical frameworks to analyze the data that is being generated through those screens and to integrate it within other large-scale biological data sets.
Dr. Shalem’s research focuses on translational target discovery for a range of neurodegenerative diseases. He combines technology development of large-scale CRISPR-based perturbation screens with application of such technology together with additional genomic approaches.